Antipsychotics — Second‑generation antipsychotic pharmacy coverage
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.659 alerts
Get alerted when Policy 5.01.659 changes without checking for updates manually.
Monitor payer policy activity
Pharmacy policy defining medical necessity criteria, prior authorization requirements, age and quantity limits, and documentation expectations for oral second‑generation antipsychotic products managed under the pharmacy benefit.
Added coverage criteria for Bysanti (milsaperidone).
Updated criteria for Cobenfy (xanomeline and trospium chloride) to add a quantity limit of 60 capsules per 30 days.
Removed brand clozapine and brand clozapine ODT from the policy as they are no longer on the market.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.